Currently, there are 1.25B common shares owned by the public and among those 1.24B shares have been available to trade.
Insiders at the company have transacted a total of 63 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 34 of these insider trades were purchases, accounting for 153,873 shares. Insider sales of the common stock occurred on 29 occasions, with total insider shares sold totaling 104,585 shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
However, the script later moved the day high at 73.14, up 0.10%. The company’s stock has a 5-day price change of 1.36% and -3.13% over the past three months. GILD shares are trading -9.86% year to date (YTD), with the 12-month market performance down to -9.47% lower. It has a 12-month low price of $71.37 and touched a high of $87.86 over the same period. GILD has an average intraday trading volume of 7.36 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -2.50%, -7.94%, and -6.07% respectively.
Institutional ownership of Gilead Sciences, Inc. (NASDAQ: GILD) shares accounts for 87.10% of the company’s 1.25B shares outstanding.
It has a market capitalization of $90.99B and a beta (3y monthly) value of 0.21. The stock’s trailing 12-month PE ratio is 16.21, while the earnings-per-share (ttm) stands at $4.50. The company has a PEG of 3.17 and a Quick Ratio of 1.27 with the debt-to-equity ratio at 1.12. Price movements for the stock have been influenced by the stock’s volatility, which stands at 1.28% over the week and 1.68% over the month.
Earnings per share for the fiscal year are expected to increase by 5.71%, and 5.02% over the next financial year. EPS should grow at an annualized rate of 5.12% over the next five years, compared to 1.55% over the past 5-year period.
Looking at the support for the GILD, a number of firms have released research notes about the stock. Truist stated their Hold rating for the stock in a research note on February 22, 2024, with the firm’s price target at $91-$82. Deutsche Bank coverage for the Gilead Sciences, Inc. (GILD) stock in a research note released on November 09, 2023 offered a Hold rating with a price target of $75. BofA Securities was of a view on September 08, 2023 that the stock is Buy, while HSBC Securities gave the stock Reduce rating on September 06, 2023, issuing a price target of $71. Barclays on their part issued Equal Weight rating on July 24, 2023.
